Issues and advances in the pharmacotherapy of asthma
Identifieur interne : 002E71 ( Main/Exploration ); précédent : 002E70; suivant : 002E72Issues and advances in the pharmacotherapy of asthma
Auteurs : H. William Kelly [États-Unis]Source :
- Journal of Clinical Pharmacy and Therapeutics [ 0269-4727 ] ; 1992-10.
English descriptors
- Teeft :
- Agonist, Airway, Airway inflammation, Airways inflammation, Allergen, Allergen challenge, Allergy, American review, Asthma, Asthma symptoms, Asthmatic, Bronchial asthma, Bronchial hyperreactivity, Bronchial hyperresponsiveness, Bronchial responsiveness, Bronchoalveolar lavage, Bronchodilator, Bronchoprovocation, Cardiac toxicity, Chronic asthma, Chronic therapy, Clinical immunology, Corticosteroid, Corticosteroiddependent asthma, Cyclosporin, England journal, Eosinophil, Epithelial, Fenoterol, Formoterol, Histamine, Hyperresponsiveness, Immunology, Inflammation, Inflammatory, Inhaled, Inhaled corticosteroids, Internal medicine, Lung function, Mast cells, Mediator, Methacholine, Methotrexate, Nedocromil, Nedocromil sodium, Open trial, Respiratory disease, Rheumatoid arthritis, Salbutamol, Sodium cromoglycate, Steroid, Systemic corticosteroids, Terbutaline, Toxicity.
Abstract
Evidence is accumulating that inflammation of the airways is directly responsible for the increased bronchial hyperresponsiveness (BHR) and lung function obstruction in asthma. Bronchoprovocation with non‐specific, direct bronchoconstrictors (methacholine and/or histamine) can be used as an indirect measurement of inflammation. Thus bronchoprovocation is a useful method for evaluating the long‐term benefits of various therapies in asthma. The focus of asthma therapy research is now on the development of anti‐inflammatory agents. Inhaled corticosteroids are currently the most potent anti‐inflammatory agents in the treatment of asthma and so are generally the most effective in reducing BHR with long‐term use. Non‐corticosteroid anti‐inflammatory agents that are currently available are reviewed. Recent studies have suggested that regular use of inhaled broncho‐dilators may actually be detrimental in asthma. At this time the data is still inconclusive but certainly warrants the attention of practitioners and requires further research, particularly in relation to the long‐acting β2‐agonists, formoterol and salmeterol.
Url:
DOI: 10.1111/j.1365-2710.1992.tb01305.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001B07
- to stream Istex, to step Curation: 001B07
- to stream Istex, to step Checkpoint: 001C44
- to stream Main, to step Merge: 002F37
- to stream Main, to step Curation: 002E71
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Issues and advances in the pharmacotherapy of asthma</title><author><name sortKey="Kelly, H William" sort="Kelly, H William" uniqKey="Kelly H" first="H. William" last="Kelly">H. William Kelly</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0BCE4A48CE880C3F4C1162D356C233FEE8DFB3D1</idno><date when="1992" year="1992">1992</date><idno type="doi">10.1111/j.1365-2710.1992.tb01305.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-4XJMPX52-8/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001B07</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001B07</idno><idno type="wicri:Area/Istex/Curation">001B07</idno><idno type="wicri:Area/Istex/Checkpoint">001C44</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001C44</idno><idno type="wicri:doubleKey">0269-4727:1992:Kelly H:issues:and:advances</idno><idno type="wicri:Area/Main/Merge">002F37</idno><idno type="wicri:Area/Main/Curation">002E71</idno><idno type="wicri:Area/Main/Exploration">002E71</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Issues and advances in the pharmacotherapy of asthma</title><author><name sortKey="Kelly, H William" sort="Kelly, H William" uniqKey="Kelly H" first="H. William" last="Kelly">H. William Kelly</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>College of Pharmacy and School of Medicine, University of New Mexico</wicri:regionArea><wicri:noRegion>University of New Mexico</wicri:noRegion></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Correspondence address: College of Pharmacy University of New Mexico, 2502 Marble N.E., Albuquerque, NM 87131‐1066</wicri:regionArea><placeName><region type="state">Nouveau-Mexique</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Clinical Pharmacy and Therapeutics</title><title level="j" type="alt">JOURNAL OF CLINICAL PHARMACY THERAPEUTICS</title><idno type="ISSN">0269-4727</idno><idno type="eISSN">1365-2710</idno><imprint><biblScope unit="vol">17</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="271">271</biblScope><biblScope unit="page" to="281">281</biblScope><biblScope unit="page-count">11</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1992-10">1992-10</date></imprint><idno type="ISSN">0269-4727</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0269-4727</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Agonist</term><term>Airway</term><term>Airway inflammation</term><term>Airways inflammation</term><term>Allergen</term><term>Allergen challenge</term><term>Allergy</term><term>American review</term><term>Asthma</term><term>Asthma symptoms</term><term>Asthmatic</term><term>Bronchial asthma</term><term>Bronchial hyperreactivity</term><term>Bronchial hyperresponsiveness</term><term>Bronchial responsiveness</term><term>Bronchoalveolar lavage</term><term>Bronchodilator</term><term>Bronchoprovocation</term><term>Cardiac toxicity</term><term>Chronic asthma</term><term>Chronic therapy</term><term>Clinical immunology</term><term>Corticosteroid</term><term>Corticosteroiddependent asthma</term><term>Cyclosporin</term><term>England journal</term><term>Eosinophil</term><term>Epithelial</term><term>Fenoterol</term><term>Formoterol</term><term>Histamine</term><term>Hyperresponsiveness</term><term>Immunology</term><term>Inflammation</term><term>Inflammatory</term><term>Inhaled</term><term>Inhaled corticosteroids</term><term>Internal medicine</term><term>Lung function</term><term>Mast cells</term><term>Mediator</term><term>Methacholine</term><term>Methotrexate</term><term>Nedocromil</term><term>Nedocromil sodium</term><term>Open trial</term><term>Respiratory disease</term><term>Rheumatoid arthritis</term><term>Salbutamol</term><term>Sodium cromoglycate</term><term>Steroid</term><term>Systemic corticosteroids</term><term>Terbutaline</term><term>Toxicity</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Evidence is accumulating that inflammation of the airways is directly responsible for the increased bronchial hyperresponsiveness (BHR) and lung function obstruction in asthma. Bronchoprovocation with non‐specific, direct bronchoconstrictors (methacholine and/or histamine) can be used as an indirect measurement of inflammation. Thus bronchoprovocation is a useful method for evaluating the long‐term benefits of various therapies in asthma. The focus of asthma therapy research is now on the development of anti‐inflammatory agents. Inhaled corticosteroids are currently the most potent anti‐inflammatory agents in the treatment of asthma and so are generally the most effective in reducing BHR with long‐term use. Non‐corticosteroid anti‐inflammatory agents that are currently available are reviewed. Recent studies have suggested that regular use of inhaled broncho‐dilators may actually be detrimental in asthma. At this time the data is still inconclusive but certainly warrants the attention of practitioners and requires further research, particularly in relation to the long‐acting β2‐agonists, formoterol and salmeterol.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Nouveau-Mexique</li></region></list><tree><country name="États-Unis"><noRegion><name sortKey="Kelly, H William" sort="Kelly, H William" uniqKey="Kelly H" first="H. William" last="Kelly">H. William Kelly</name></noRegion><name sortKey="Kelly, H William" sort="Kelly, H William" uniqKey="Kelly H" first="H. William" last="Kelly">H. William Kelly</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E71 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002E71 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:0BCE4A48CE880C3F4C1162D356C233FEE8DFB3D1
|texte= Issues and advances in the pharmacotherapy of asthma
}}
| This area was generated with Dilib version V0.6.33. |  |